Bladder cancer: squamous histology carries worse prognosis

  • Matulay JT & al.
  • Urol Oncol
  • 28 Jan 2019

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Patients with invasive squamous cell carcinoma (SCC) of the bladder show worse prognosis vs those with urothelial carcinoma (UC) histology.
  • Neoadjuvant chemotherapy (NACT) showed OS benefit in patients with UC vs radical cystectomy (RC) alone, but for not those with SCC histology.

Why this matters

  • More effective therapies are needed for invasive SCC of the bladder.

Study design

  • Study of 394,956 patients with bladder cancer from the National Cancer Database.
  • Funding: None.

Key results

  • 63,482 patients had clinically localized muscle-invasive bladder cancer; of those, 1.2% had SCC histology.
  • At diagnosis, 70% of patients with SCC were presented with cT2-4 vs 19% of those with UC histology.
  • OS was worse in patients with SCC vs UC clinically localized muscle-invasive bladder cancer (9.6 vs 24.6 months; P<.01 style="list-style-type:circle;">
  • Worse OS was observed in patients with SCC across stages (all P<.01>
  • SCC histology showed an independent association with an increased risk for death (HR, 1.79; P<.01>
  • Median OS in patients with SCC who received RC alone vs NACT was 25.4 vs 34.0 months (P=.34).
  • Receipt of NACT was associated with improved OS in patients with UC (HR, 0.83; P<.01 but not in those with scc p=".65)" vs rc alone.>

    Limitations

    • Retrospective design.
  • Please confirm your acceptance

    To gain full access to GPnotebook please confirm:

    By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

    Submit